Title: Study of intralesional Bleomycin sclerotherapy in hemangiomas
Authors: Satyendra K. Tiwary, MS, FICS, Ritesh Kumar Gupta, MBBS, MS, Puneet Kumar, MS, Ajay K Khanna, MS, FACS
DOI: https://dx.doi.org/10.18535/jmscr/v7i12.73
Abstract
Introduction: Hemangiomas are the most common tumors in infancy and are also the most common tumors of the head and neck in infancy. The incidence of Hemangiomas in the first 3 days of life is 1.1% to 2.6% and increases to 8.7% to 12.7% between the ages of 1 month and 1 year of life. We used Bleomycin sclerosent in the treatment of Hemangiomas and effect of intralesional Bleomycin sclerotherapy in Hemangiomas was studied.
Methods: For Intralesional Bleomycin Sclerotherapy, the lesion was confirmed by Doppler guided ultrasonography so as to know exact location, size of the lesion. The suitable pucture pathway was also to be determined through multiple scanning. A puncture needle was pricked into lesions under ultrasound guidance. After multiple scanning and the aspiration of the blood confirmed its intralesional position, the injection of bleomycin A5 prepared with 5 ml of lignocaine 2%, filled in the externally connected syringe, was carried out through the inspection of ultrasonography. A multi-point injection was used so as to uniformly distribute bleomycin A5 in the lesion area.
Results: 50 patients with peripheral hemangiomas were studied. Nearly all the patients of Hemangiomas who underwent sclerotherapy responded to treatment and response of therapy was assessed clinically and on basis of USG color Doppler according to the Weidong Shou standards into cured, basically cured, improved and ineffective. The result was, 42 patients with Hemangiomas were cured (84%), 6 patients basically cured (12%), 2 patients improved (4%) and none inefective.
Conclusion: 50 patients with Hemangiomas underwent sclerotherapy by intralesional Bleomycin with a cured response in 84%.
Keywords: Bleomycin, Hemangioms, Sclerotherapy, Doppler USG.
References
- Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg. 1983;18:894-900.
- Marler JJ, Fishman SJ ,Kilroy SM, Fang J, Upton J, Mulliken JB, Burrows PE, Zurakowski D, Folkman J, Moses MA. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Paediatrics 2010; 116: 38-45.
- Juan Cabrera, Juan Cabrera, Jr, M Antonia Garcia-Olmedo et al. Treatment of venous malformations with sclerosant in microfoam form. Arch dermatol 2003; 139:1409-16.
- Erin F.D. Mathes, Anita N. Haggstrom, Christopher Dowd et al. Clinical characteristics and management of vascular anomalies. Arch dermatol 2010:140:979-83.
- Pedro Redondo, Antonio Martinez-Cuesta, Emilio G. Quetglas et al. Active angiogenesis in an extensive arteriovenous vascular malformation. Arch dermatol 2009, 143:1043-45.
- Enjolras O, Breviere GM, Roger G, et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr. 2004;11:99–107
- Odile Enjolras, Rene Chapot and Jean Jacques Merland. Vascular anomalies and the growth of limbs: a review. Journal of Pediatric Orthopaedics. 2004; 13:349-57.
- Gangopadhaya AN, Pandey A. Hemangiomas In: Manual of Vascular surgery. AK Khanna, Puneet (Eds.). Jaypee Brothers Medical Publishers (P) Ltd, 2010,342
- McHeik JN, Renauld V, Duport G, et al. Surgical treatment of haemangioma in infants. Br J Plast Surg. 2005;58(8):1067–72
- Hou et al., A clinical study of ultrasound-guided intralesional injection of bleomycin A5 on venous malformation in cervical-facial region in China. J Vasc Surg 2010;51:940-5.
- Hassan et al., Noninvasive Management of Hemangioma and Vascular Malformation Using Intralesional Bleomycin Injection. Annals of Plastic Surgery 2013; 70: 1
- Muir T, Kirsten M, Fourie P, Dippenaar N. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int 2004;19:766–73.
- Zhang L, Lin X, Wang W, et al. Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg. 2005;116(1): 200-04.